Hemofília: vizsgálatok itt: Dél-afrikai Köztársaság
7 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Where
- Parktown
- Életkor
- 12 év and over
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416604 · EU 2025-522435-33-00 - 3. fázisTaking peopleA Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
- Where
- Parktown, Johannesburg
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07830732 · EU 2026-525529-19-00 - 3. fázisTaking peopleOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Where
- Benoni, Johannesburg
- Életkor
- 1 év to 74 év
- People
- 245 worldwide
- Run by
- Pfizer
See details and how to joinNCT05145127 · EU 2022-500470-33-00 - 3. fázisTaking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- Where
- Parktown
- Életkor
- 12 év and over
- People
- 138 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416526 · EU 2025-522434-32-00 - 3. fázisTaking peopleA Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Where
- Benoni, Johannesburg
- Életkor
- 1 év to 17 év
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05611801 · EU 2022-500495-65-00 - 3. fázisTaking peopleEfficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- Where
- Johannesburg
- Életkor
- 18 év and over
- People
- 35 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06003387 · EU 2023-509590-23-00 - 4. fázisCsak meghívásosA Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
- Where
- Johannesburg
- Életkor
- 18 év and over
- People
- 172 worldwide
- Run by
- BioMarin Pharmaceutical
See details and how to joinNCT05768386 · EU 2023-507749-27-00